Tactiva Therapeutics inks $35 mln Series A

Tactiva Therapeutics, a cancer immunotherapy company, has secured $35 million in Series A financing. Panacea Healthcare Partners led the round with participation from other investors that included Vi Ventures and Efung Capital.

Source: Press Release